聚乙二醇非格司亭
外观
临床资料 | |
---|---|
商品名 | Neulasta |
生物相似药 | pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, pegfilgrastim-fpgk, pegfilgrastim-jmdb, pegfilgrastim-pbbk, Cegfila,[1] Filpegla,[2] Fulphila,[3] Fylnetra,[4] Grasustek,[5] Lapelga, Neutropeg, Niopeg,[6] Nyvepria, Pelgraz, Pelmeg,[7] Ristempa, Stimufend,[8][9] Tezmota,[10] Udenyca, Ziextenzo[11][12] |
AHFS/Drugs.com | Monograph |
MedlinePlus | a607058 |
核准状况 |
|
怀孕分级 | |
给药途径 | 皮下注射 |
药物类别 | 造血因子、集落刺激因子、免疫刺激剂 |
ATC码 | |
法律规范状态 | |
法律规范 | |
药物动力学数据 | |
生物半衰期 | 15–80 小时 |
识别信息 | |
| |
CAS号 | 208265-92-3 |
IUPHAR/BPS | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.169.155 |
化学信息 | |
化学式 | C845H1343N223O243S9 |
摩尔质量 | 18,802.90 g·mol−1 |
聚乙二醇非格司亭(Pegfilgrastim)又译为培非格司亭,用于治疗化学疗法或放射治疗后造成的嗜中性白血球低下[19] [20]。作用与非格司亭相似,但药效较长,无需频繁地给药[19]。此药物由皮下注射给药[21]。
常见副作用包括骨痛[21]。其他副作用包括可能脾脏受伤、急性呼吸窘迫症候群和严重过敏反应[19]。它是非格司亭的聚乙二醇化后的药物,而非格司亭是一种由基因重组制造的白血球生长激素(GCSF)[20]。它会使骨髓内的白血球增生[21]。
培非格司亭于 2002 年在美国、欧洲和澳大利亚获准用于医疗用途[19] [21] [22]。它被列入世界卫生组织基本药物标准清单[23]。已有生物相似药上市,价格约为原厂的六至七成[24] [25]。
参考文献
[编辑]- ^ 1.0 1.1 Cegfila EPAR. European Medicines Agency (EMA). [2020-04-02]. (原始内容存档于2020-06-11).
- ^ 2.0 2.1 2.2 Filpegla | Therapeutic Goods Administration (TGA). [2022-12-18]. (原始内容存档于2022-12-18).
- ^ 3.0 3.1 Fulphila EPAR. European Medicines Agency (EMA). 2018-09-24 [2020-04-02]. (原始内容存档于2020-06-11).
- ^ 4.0 4.1 Fylnetra- pegfilgrastim injection. DailyMed. 2022-05-26 [2022-06-19]. (原始内容存档于2022-07-03).
- ^ 5.0 5.1 Grasustek EPAR. European Medicines Agency (EMA). 2019-04-24 [2020-04-02]. (原始内容存档于2020-06-11).
- ^ 6.0 6.1 Summary Basis of Decision for Niopeg. Drug and Health Products Portal. 2012-09-01 [2024-12-17].
- ^ 7.0 7.1 Pelmeg EPAR. European Medicines Agency (EMA). 2018-09-24 [2020-04-02]. (原始内容存档于2020-06-11).
- ^ 8.0 8.1 Stimufend- pegflilgrastim-fpgk injection, solution. DailyMed. 2022-09-15 [2023-01-21]. (原始内容存档于2023-01-21).
- ^ 9.0 9.1 Stimufend EPAR. European Medicines Agency (EMA). [2022-04-04]. (原始内容存档于2022-04-21).
- ^ Tezmota. NPS MedicineWise. 2021-07-15 [2022-02-19]. (原始内容存档于2022-09-29).
- ^ 11.0 11.1 Ziextenzo EPAR. European Medicines Agency (EMA). 2018-09-24 [2020-04-02]. (原始内容存档于2020-06-11).
- ^ Summary Basis of Decision (SBD) for Ziextenzo. Health Canada. 2014-10-23 [2022-05-29]. (原始内容存档于2022-05-30).
- ^ 13.0 13.1 Ziextenzo. Therapeutic Goods Administration (TGA). 2019-12-13 [2020-08-25]. (原始内容存档于2021-10-20).
- ^ Pegfilgrastim Use During Pregnancy. Drugs.com. 2019-12-09 [2020-07-13]. (原始内容存档于2020-12-05).
- ^ Neulasta Pre-Filled Syringe - Summary of Product Characteristics (SmPC). (emc). 2021-06-01 [2021-10-11]. (原始内容存档于2021-01-15).
- ^ Neulasta On Body Injector - Summary of Product Characteristics (SmPC). (emc). [2021-10-11]. (原始内容存档于2021-01-17).
- ^ Neulasta- pegfilgrastim kit Neulasta- pegfilgrastim injection. DailyMed. [2021-07-14]. (原始内容存档于2021-07-15).
- ^ Neulasta EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-02]. (原始内容存档于2020-06-11).
- ^ 19.0 19.1 19.2 19.3 Pegfilgrastim Monograph for Professionals. Drugs.com. 2019-08-22 [2020-06-11]. (原始内容存档于2016-03-07).
- ^ 20.0 20.1 Neulasta- pegfilgrastim kit Neulasta- pegfilgrastim injection. DailyMed. [2021-07-14]. (原始内容存档于2021-07-15).
- ^ 21.0 21.1 21.2 21.3 Neulasta EPAR. European Medicines Agency (EMA). [2020-04-02]. (原始内容存档于2020-06-11).
- ^ NEULASTA pegfilgrastim rbe 6mg/0.6mL injection syringe with stelmi needle shield. [2021-10-27].
- ^ World Health Organization. The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. 2023. WHO/MHP/HPS/EML/2023.02.
- ^ Pegfilgrastim Prices, Coupons & Savings Tips - GoodRx. GoodRx.
- ^ Pegfilgrastim-Bmez Prices, Coupons & Savings Tips - GoodRx. GoodRx. [2021-10-27].